登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C20H25ClN2O5 · C6H5SO3H
化学文摘社编号:
分子量:
567.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
amlodipine
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC
InChI
1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
InChI key
ZPBWCRDSRKPIDG-UHFFFAOYSA-N
Gene Information
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
General description
本产品按照现行药典要求提供和指定。所有为支持本产品而提供的信息，包括 SDS 和任何产品信息小册子，均由药典颁发机构制定和发布。如需进一步的信息和支持，请访问现行药典网站。如需进一步信息和支持，请访问现行药典网站。
Application
苯磺酸氨氯地平USP参考标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 氨氯地平和阿托伐他汀片
- 氨氯地平和盐酸贝那普利胶囊
- 氨氯地平和奥美沙坦酯片
- 氨氯地平和缬沙坦片
- 氨氯地平苯磺酸盐
- 氨氯地平苯磺酸盐片
- 氨氯地平复方口服混悬液
Biochem/physiol Actions
氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物，作用于 Ca V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长，对雄性大鼠有抗生殖作用。
苯磺酸氨氯地平是一种 L 型钙通道阻滞剂。
Analysis Note
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。
Other Notes
可能适用相应的销售限制。
Still not finding the right product?
Explore all of our products under 苯磺酸氨氯地平(钙拮抗药)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Roy Blank
Drugs of today (Barcelona, Spain : 1998), 42(3), 157-175 (2006-04-22)
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood pressure-lowering agent with pleiotropic effects, and atorvastatin calcium, a statin with lipid-lowering as well as pleiotropic
Abdel Naser Zaid et al.
Pakistan journal of pharmaceutical sciences, 27(4), 755-762 (2014-07-13)
The aim of this study was to formulate a film-coated Valsartan/Amlodipine (VS/AM) immediate release tablets and to evaluate their in vivo release profile. VS/AM core tablets were manufactured using dry granulation method. Opadry aqueous coating dispersion was used as film
Roy Blank et al.
Drugs of today (Barcelona, Spain : 1998), 43(3), 157-177 (2007-03-24)
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering agent, and atorvastatin calcium, a statin with lipid-lowering antiatherosclerotic properties. Amlodipine and atorvastatin have been demonstrated
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1029501-350MG | 04061838670069 |